Naturally the moleclues are very exciting and all
that, those few pages of the s-4 make a good read.
But I was also happy to see that Infinity has a
license to Nexus (IRORI) RF tag technology. I had
always wondered if there was something there, maybe so.
Also, I have found at the top of page 89:
"At March 31, 2006, Infinity had cash, cash
equivalents and available-for-sale marketable securities
of $23.9 million " I had posted over on my thread that
I thought they had less than $5M, but that is not the case.
So, they will close this deal sometime over the summer and
ought to have three years of cash. Although, I would say
if their molecules are good, they seem to have outlined
many ways of burning a lot of cash very fast in clinical
trials! So maybe the cash will be gone in two years, but
a couple of aacr/asco cycles, and they can raise cash
when they have to at higher valuations and I won't mind
being diluted.
Ha! I won't have my INFI for months and I am
already imagining how I will tough out the
inevitible cycles of dilution on the way to
market. It'll be a long haul, but fun to watch. |
